The bioavailability of pollen bioactive compounds for humans is limited. In this study, our aim was to enhance the health-related benefits of pollen by fermentation with a Kombucha/SCOBY (symbiotic culture of bacteria and yeasts) consortium. We performed the fermentation of pollen suspended from the beginning with SCOBY on sweetened green tea or on Kombucha vinegar, by adding pollen after 20 days of Kombucha fermentation. We analyzed: formation of bioactive compounds (anti-oxidant polyphenols, soluble silicon, hydroxy-acids, short chain fatty acids—SCFA); parameters related to Kombucha fermentation (dynamics of lactic acid bacteria—LAB, formation of organic acids, soluble sugar evolution on Kombucha vinegar); the influence of Kombucha fermentation on pollen morphology and ultrastructure; in vitro cytotoxic and antitumoral effects of the Kombucha fermented pollen. The pollen addition increases LAB proportion in the total number of SCOBY microbial strains. SEM images highlight the adhesion of the SCOBY bacteria to pollen. Ultrastructural analysis reveals the release of the pollen content. The content of bioactive compounds (polyphenols, soluble silicon species and SCFA) is higher in the fermented pollen and the product shows a moderate antitumoral effect on Caco-2 cells. The health benefits of pollen are enhanced by fermentation with a Kombucha consortium.

In the past decade, the probiotic market has grown rapidly, both for foods and supplements intended to enhance wellness in healthy individuals. Different lactic acid bacteria (LAB), especially Lactobacillus spp., of different origins have already been used to develop commercial probiotic products. Nowadays, LAB new alternative sources, such as non-dairy fermented food products, are being exploited. One such source is Kombucha, a fermented low-alcohol beverage made of tea leaves. In this regard, we tested seven Pediococcus spp. strains isolated from a local industrial Kombucha for their biotechnological potential. Two, out of the seven isolates, identified as Pediococcus pentosaceus (L3) and Pediococcus acidiliactici (L5), were selected as successful candidates for the food industry, due to their probiotic and technological properties. In regard to their resistance in the gastro-intestinal tract, both selected strains were tolerant to a pH of 3.5, presence of 0.3% pepsin, and 0.5% bile salt concentration. On the antagonistic side, the fresh suspension of selected isolates had high inhibitory activity against pathogenic bacteria, such as Salmonella enterica Typhimurium, Listeria monocytogenes, Listeria ivanovii, Bacillus cereus, Proteus hauseri, and methicillin resistant Staphylococcus aureus. In addition, moderate to high inhibitory activity was noticed against foodborne molds (e.g., Penicillium expansum and Penicillium digitatum). These safety issues were supported by their negative hemolytic activity and good antioxidant potential (56–58%). Selected isolates were sensitive to ampicillin, penicillin, erythromycin, and lincomycin, while a broad range of other antibiotics were not effective inhibitors. On the technological side, both strains tolerated 5% NaCl and, during the freeze-drying process, had a good survival rate (86–92%). The selected Pediococcus strains have proven properties to be used for further development of functional products.

Background: Probiotics have recently been applied in aquaculture as eco-friendly alternatives to antibiotics to improve fish health, simultaneously with the increase of production parameters. The present study aimed to investigate the functional potential of lactic acid bacteria (LAB) isolated from the gut of Tilapia (Oreochromis niloticus) originating from the aquaculture farm of Oceanologic Research Center in Ivory Coast. Results: Twelve LAB strains were identified by 16 S rDNA gene sequence homology analysis belonging to two genera Pediococcus (P. acidilactici and P. pentosaceus) and Lactobacillus (L. plantarum) with a predominance of P. acidilactici. Several aspects including functional, storage, and safety characteristics were taken into consideration in the selection process of the native LAB isolates as potential probiotics. All LAB isolates showed high antagonistic activity against bacterial pathogens like Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Staphylococcus aureus. In addition, the LAB isolates exhibited different degrees of cell surface hydrophobicity in the presence of hexane, xylene, and chloroform as solvents and a good ability to form biofilm. The strong antioxidant activity expressed through the DPPH scavenging capacity of LAB intact cells and their cell-free supernatants was detected. LAB strains survived between 34.18% and 49.9% when exposed to low pH (1.5) and pepsin for 3 h. In presence of 0.3% bile salts, the growth rate ranged from 0.92 to 21.46%. Antibiotic susceptibility pattern of LAB isolates showed sensitivity or intermediate resistance to amoxicillin, cephalothin, chloramphenicol, imipenem, kanamycin, penicillin, rifampicin, streptomycin, tetracycline and resistance to oxacillin, gentamicin, and ciprofloxacin. No significant difference in antibiotic susceptibility pattern was observed between P. acidilactici and P. pentosaceus strains. The non-hemolytic activity was detected. Following the analysis of the enzyme profile, the ability of LAB isolates to produce either lipase or β-galactosidase or both enzymes was highlighted. Furthermore, the efficacy of cryoprotective agents was proved to be isolate-dependent, with LAB isolates having a high affinity for D-sorbitol and sucrose. Conclusion: The explored LAB strains inhibited the growth of pathogens and survived after exposure to simulated gastrointestinal tract conditions. The safety and preservative properties are desirable attributes of these new probiotic strains hence recommended for future food and feed applications.

Microbial infections, and especially microbial resistance, are critical and actual problems that require targeted and efficient therapeutic intervention. Natural-based solutions are a viable alternative, at least for complementary therapy, due to few or no side effects and high safety and efficacy levels. The aim of this study was to demonstrate the potential use of a patented formula based on Achillea millefolium, Origanum vulgare, and Lychnis coronaria species as an antibacterial ingredient, mainly for skin and mucosal infections, in order to support its pharmaco-cosmetic application. The chemical composition of the formula was analyzed by HPLC and spectrophotometric methods. Furthermore, antioxidant and antimicrobial activity were evaluated. To determine the formula’s safety for topical application, it was used on a reconstructed human epidermal model. The formula showed inhibitory activity on both Gram-positive and Gram-negative bacteria, respectively, moderate inhibition on B. cereus, Kocuria kristinae, P. aeurginosa, S. enterica Typhimurium, methicillin-resistant and methicillin-sensible S. aureus, as well as high inhibition on S. epidermidis, Serratia marescens, and Streptococcus pyogenes. The developed product was biochemically characterized for its content in polyphenols, triterpenes, and polyphenol carboxylic acids. The formula was proven to have a nonirritant effect on the human epidermis and important antioxidant activity.